SCL Science

SCL Science Debt Growth

The Year-over-Year Debt Growth of SCL Science (246960.KQ) as of Nov 18, 2026 is 231.81 %. In the previous year, Year-over-Year Debt Growth was -46.19 % — a change of -601.83% (higher).

Debt Growth

231.81 %

YoY

-601.83%

Last updated:

Year-over-Year Debt Growth of SCL Science is 2025 231.81 % . Year-over-Year Debt Growth of SCL Science was 2024 -46.19 % . It decreases by -601.83% higher compared to the previous year.

The SCL Science Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2018
60.00 KRW
Jan 1, 2019
-43.14 KRW
Jan 1, 2020
477.92 KRW
Jan 1, 2021
553.31 KRW
Jan 1, 2022
-39.65 KRW
Jan 1, 2023
-34.26 KRW
Jan 1, 2024
-46.19 KRW
Jan 1, 2025
231.81 KRW
The SCL Science Debt Growth history
YEARDebt GrowthYoY
231.81 %-601.83%
-46.19 %+34.83%
-34.26 %-13.59%
-39.65 %-107.17%
553.31 %+15.77%
477.92 %-1,207.73%
-43.14 %-171.91%
60.00 %-160.00%
-100.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCL Science Stock analysis

What does SCL Science do? SCL Science Inc, listed on the Korean stock exchange with ticker 246960.KQ and ISIN KR7246960009, is a healthcare company headquartered in Seoul, South Korea. The company went public on February 1, 2019, as indicated by its IPO date. SCL Science Inc operates within the healthcare sector, focusing on the development and commercialization of medical products. According to the provided information, the company manufactures and sells hemostatic medical agents, which are used to control bleeding in medical procedures. The company's products include medical hemostats and sealants that utilize biomimetic technology, a technology inspired by natural biological processes. The company's website is innotherapy.com, which may provide further details about its products and services. SCL Science Inc is based in Seoul, South Korea, and its primary business activities are centered around the healthcare industry, specifically in the field of hemostatic solutions. The company's focus on biomimetic technology suggests an innovative approach to developing medical products that mimic natural biological mechanisms. The company's operations are likely aimed at providing medical professionals with effective tools for managing bleeding during surgical and other medical procedures. The company's market presence is within South Korea, though it may have international reach through its website and product distribution channels. The information provided does not include details on the company's revenue, market share, or specific competitors, nor does it mention any acquisitions or key personnel beyond the general description of its business activities. SCL Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCL Science stock

Year-over-Year Debt Growth of SCL Science is 231.81 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth SCL Science since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's SCL Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — SCL Science

All Key Metrics — SCL Science